Anti-ARID1A polyclonal antibody in the study ”Relevance of ARID1A Mutations in Endometrial Carcinomas”

March, 2022 (Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy)

Endometrial cancer is one of the most common cancers of the female reproductive system.

It develops in the cells that form the inner lining of the uterus or the endometrium and shares genomic features with some forms of ovarian, breast, and colorectal cancer.

ARID1A is a recently identified tumor suppressor gene mutated in approximately 50% of ovarian cells and 30% of ovarian endometrioid carcinomas. The mutation is associated with loss of protein expression as assessed by immunohistochemistry.

Using our anti-ARID1A polyclonal antibody (HPA005456), this study led by Dario de Biase reports a good correlation between ARID1A mutations and protein immunostaining.

The results suggest that the molecular characterization of ARID1A in endometrial cancer should be associated with IHC analysis, mainly in those cases harboring “novel” ARID1A mutations or in those alterations with “uncertain” pathogenic significance.

Read the full paper:

Anti-ARID1A antibody specifications: